-
Company Profile
![]()
Rich Products Corp – Company Profile
Rich Products Corp (Rich Products) is a manufacturer and marketer of frozen foods. The company's product portfolio comprises toppings and icings, cakes and desserts, pizzas nut free cookies, bakery products, culinary solutions, beverages, sweet treats, and ice cream cakes. Rich Products markets its products under Farm Rich, Bettercreme, On Top, Whip Topping, Versatie, Tres Riches, Gold Label, Icehot, and Treat shops brand names. The company serves grocery stores, cafes, restaurants, bakeries, schools, and universities. It has business presence across the...
Add to Basket -
Product Insights
Rich Products – Rich Products Manufacturing Facility Expansion – Texas
Equip yourself with the essential tools needed to make informed and profitable decisions with our Rich Products - Rich Products Manufacturing Facility Expansion - Texas report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
Northwood – Amenity Rich Office Tower – North Carolina
Equip yourself with the essential tools needed to make informed and profitable decisions with our Northwood - Amenity Rich Office Tower - North Carolina report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
CNNC Rich Engy – Xinglong Wind Farm 135 MW – Heilongjiang
Equip yourself with the essential tools needed to make informed and profitable decisions with our CNNC Rich Engy - Xinglong Wind Farm 135 MW - Heilongjiang report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
Azure Rich Grp/ Wyndham Hotels – Jomtien Beach Resort – Bangkok
Equip yourself with the essential tools needed to make informed and profitable decisions with our Azure Rich Grp/ Wyndham Hotels - Jomtien Beach Resort - Bangkok report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
Rich Goldman Hldg – Ballyclare Western Relief Road Development – Antrim Borough
Equip yourself with the essential tools needed to make informed and profitable decisions with our Rich Goldman Hldg - Ballyclare Western Relief Road Development - Antrim Borough report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Product Insights
EDF Renewables – Rich Road Solar Energy Center 240 MW – New York
Equip yourself with the essential tools needed to make informed and profitable decisions with our EDF Renewables - Rich Road Solar Energy Center 240 MW - New York report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PTG-100 in Celiac Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PTG-100 in Celiac DiseaseDrug Details:PTG-100 is under development for the treatment of celiac disease. These are...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLIF-06 in Wounds
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SLIF-06 in WoundsDrug Details:F06-C40 is under investigation for the treatment of hypertrophic scars, diabetic foot ulcers...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLIF-06 in Hypertrophic Scars
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SLIF-06 in Hypertrophic ScarsDrug Details:F06-C40 is under investigation for the treatment of hypertrophic scars, diabetic foot...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NEU-411 in Parkinson’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NEU-411 in Parkinson's Disease Drug Details: NEU-411 is under development for the treatment of Parkinson's...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in Primary Mediastinal B-Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Polatuzumab Vedotin in Primary Mediastinal B-Cell LymphomaDrug Details:Polatuzumab vedotin (Polivy / Ropolivy) is a monoclonal antibody,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Polatuzumab Vedotin in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug Details:Polatuzumab vedotin (Polivy / Ropolivy) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in Burkitt Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Polatuzumab Vedotin in Burkitt LymphomaDrug Details:Polatuzumab vedotin (Polivy / Ropolivy) is a monoclonal antibody, acts as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in Thymic Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Polatuzumab Vedotin in Thymic CarcinomaDrug Details:Polatuzumab vedotin (Polivy / Ropolivy) is a monoclonal antibody, acts as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in T-Cell Lymphomas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Polatuzumab Vedotin in T-Cell Lymphomas Drug Details:Polatuzumab vedotin (Polivy / Ropolivy) is a monoclonal antibody, acts...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NEU-723 in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.NEU-723 in Parkinson's Disease Drug Details:NEU-723 is under development for the treatment of Parkinson's disease. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rozanolixizumab in Fibromyalgia (Fibromyalgia Syndrome)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rozanolixizumab in Fibromyalgia (Fibromyalgia Syndrome) Drug Details: Rozanolixizumab (Rystiggo) acts as an anti inflammatory agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rozanolixizumab in Demyelinating Diseases
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rozanolixizumab in Demyelinating Diseases Drug Details: Rozanolixizumab (Rystiggo) acts as an anti inflammatory agent. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Petosemtamab in Penile Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Petosemtamab in Penile CancerDrug Details:Petosemtamab (MCLA-158) is under development for the treatment of metastatic colorectal cancer...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.